{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:32:30Z","timestamp":1766748750096,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004564","name":"ministarstvo prosvete, nauke i tehnolo\u0161kog razvoja","doi-asserted-by":"publisher","award":["41012"],"award-info":[{"award-number":["41012"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["690876"],"award-info":[{"award-number":["690876"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13318-021-00726-9","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T01:57:39Z","timestamp":1634090259000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights"],"prefix":"10.1007","volume":"47","author":[{"given":"Ivana","family":"Raj\u0161i\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-4095","authenticated-orcid":false,"given":"Slavica","family":"Lazarevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"\u0110ani\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Mooranian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u0161a","family":"Vukmirovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Golo\u010dorbin-Kon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"4","key":"726_CR1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cll.2011.08.016","volume":"31","author":"CJ Harrison","year":"2011","unstructured":"Harrison CJ. Acute lymphoblastic leukemia. Clin Lab Med. 2011;31(4):631\u201347.","journal-title":"Clin Lab Med"},{"issue":"15","key":"726_CR2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"C-H Pui","year":"2004","unstructured":"Pui C-H, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"726_CR3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6): e577.","journal-title":"Blood Cancer J"},{"key":"726_CR4","doi-asserted-by":"crossref","unstructured":"Mantadakis E, Cole PD, Kamen BA. High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy. 2005;25(5):748\u201355.","DOI":"10.1592\/phco.25.5.748.63584"},{"issue":"1","key":"726_CR5","first-page":"61","volume":"62","author":"SL Cooper","year":"2015","unstructured":"Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin. 2015;62(1):61\u201373.","journal-title":"Pediatr Clin"},{"issue":"16","key":"726_CR6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541\u201352.","journal-title":"N Engl J Med"},{"key":"726_CR7","doi-asserted-by":"crossref","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36(7):503\u201317.","DOI":"10.1097\/MPH.0000000000000206"},{"issue":"3","key":"726_CR8","first-page":"168","volume":"65","author":"H Tian","year":"2007","unstructured":"Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate. Bull NYU Hosp Jt Dis. 2007;65(3):168\u201373.","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"3","key":"726_CR9","first-page":"313","volume":"17","author":"P Angelis-Stoforidis","year":"1999","unstructured":"Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17(3):313\u201320.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"726_CR10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76(3):907\u201312.","journal-title":"J Clin Invest"},{"key":"726_CR11","doi-asserted-by":"crossref","unstructured":"Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 2004;50(5):1370\u201382.","DOI":"10.1002\/art.20278"},{"issue":"5","key":"726_CR12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.V93.5.1677","volume":"93","author":"MG Rots","year":"1999","unstructured":"Rots MG, Pieters R, Peters GJ, Noordhuis P, van Zantwijk CH, Kaspers GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood. 1999;93(5):1677\u201383.","journal-title":"Blood"},{"issue":"1","key":"726_CR13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI118409","volume":"97","author":"E Masson","year":"1996","unstructured":"Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest. 1996;97(1):73\u201380.","journal-title":"J Clin Invest"},{"issue":"4","key":"726_CR14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/sj.leu.2403703","volume":"19","author":"VM Whitehead","year":"2005","unstructured":"Whitehead VM, Shuster JJ, Vuchich MJ, Mahoney DH Jr, Lauer SJ, Payment C, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2005;19(4):533\u20136.","journal-title":"Leukemia"},{"issue":"3","key":"726_CR15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10428190701824569","volume":"49","author":"AK Fotoohi","year":"2008","unstructured":"Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma. 2008;49(3):410\u201326.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"726_CR16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00216-012-6581-7","volume":"405","author":"E den Boer","year":"2013","unstructured":"den Boer E, Meesters RJ, van Zelst BD, Luider TM, Hazes JM, Heil SG, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS\/MS-based method. Anal Bioanal Chem. 2013;405(5):1673\u201381.","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"726_CR17","first-page":"156","volume":"30","author":"EL Hobl","year":"2012","unstructured":"Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Br\u00f6ll H, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol. 2012;30(2):156\u201363.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"726_CR18","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1158\/0008-5472.CAN-04-2810","volume":"65","author":"P Wielinga","year":"2005","unstructured":"Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005;65(10):4425\u201330.","journal-title":"Cancer Res"},{"issue":"17","key":"726_CR19","first-page":"5538","volume":"63","author":"EL Volk","year":"2003","unstructured":"Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003;63(17):5538\u201343.","journal-title":"Cancer Res"},{"key":"726_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2019.02.008","volume":"79","author":"AC Jaramillo","year":"2019","unstructured":"Jaramillo AC, Cloos J, Lemos C, Stam RW, Kaspers GJL, Jansen G, et al. Ex vivo resistance in childhood acute lymphoblastic leukemia: correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation. Leuk Res. 2019;79:45\u201351.","journal-title":"Leuk Res"},{"key":"726_CR21","doi-asserted-by":"crossref","unstructured":"Hu YH, Zhou L, Wang SS, Jing X, Guo HL, Sun F, et al. Methotrexate disposition in pediatric patients with acute lymphoblastic leukemia: what have we learnt from the genetic variants of drug transporters. Curr Pharm Des. 2019;25(6):627\u201334.","DOI":"10.2174\/1381612825666190329141003"},{"issue":"Suppl 1","key":"726_CR22","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1111\/j.1365-2125.2001.00366.x","volume":"52","author":"L Lennard","year":"2001","unstructured":"Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol. 2001;52(Suppl 1):75s\u201387s.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"726_CR23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","volume":"49","author":"T Dervieux","year":"2003","unstructured":"Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49(10):1632\u201341.","journal-title":"Clin Chem"},{"issue":"20","key":"726_CR24","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/rcm.5202","volume":"25","author":"RJ Meesters","year":"2011","unstructured":"Meesters RJ, den Boer E, de Jonge R, Lindemans J, Luider TM. Assessment of intracellular methotrexate and methotrexate-polyglutamate metabolite concentrations in erythrocytes by ultrafast matrix-assisted laser desorption\/ionization triple quadrupole tandem mass spectrometry. Rapid Commun Mass Spectrom. 2011;25(20):3063\u201370.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"1","key":"726_CR25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-018-3704-7","volume":"83","author":"J Nersting","year":"2019","unstructured":"Nersting J, Nielsen SN, Grell K, Paerregaard M, Abrahamsson J, Lund B, et al. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy. Cancer Chemother Pharmacol. 2019;83(1):53\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"726_CR26","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/rcm.4300","volume":"23","author":"L van Haandel","year":"2009","unstructured":"van Haandel L, Becker ML, Leeder JS, Williams TD, Stobaugh JF. A novel high-performance liquid chromatography\/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom. 2009;23(23):3693\u2013702.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"726_CR27","doi-asserted-by":"crossref","unstructured":"Trujillo \u00c1M, Linares A, Sarmiento IC. Intensive chemotherapy in children with acute lymphoblastic leukemia. Interim analysis in a referral center in Colombia. Rev Fac Med Univ Nac Colomb. 2016;64:417\u201325.","DOI":"10.15446\/revfacmed.v64n3.53961"},{"issue":"2","key":"726_CR28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpba.2009.04.025","volume":"50","author":"G Chen","year":"2009","unstructured":"Chen G, Fawcett JP, Mikov M, Tucker IG. Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2009;50(2):262\u20136.","journal-title":"J Pharm Biomed Anal"},{"key":"726_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchromb.2012.08.032","volume":"907","author":"X Mo","year":"2012","unstructured":"Mo X, Wen Y, Ren B, Chen J, Xu C, Wang X, Huang M, Chen X. Determination of erythrocyte methotrexate polyglutamates by liquid chromatography\/tandem mass spectrometry after low-dose methotrexate therapy in Chinese patients with rheumatoid arthritis. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;907:41\u20138.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"6","key":"726_CR30","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","volume":"47","author":"V Maksimovic","year":"2020","unstructured":"Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, Cvejic J, Mooranian A, Al-Salami H, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699\u2013708.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"726_CR31","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/art.27434","volume":"62","author":"ML Becker","year":"2010","unstructured":"Becker ML, van Haandel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum. 2010;62(6):1803\u201312.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"726_CR32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.V76.1.44.44","volume":"76","author":"VM Whitehead","year":"1990","unstructured":"Whitehead VM, Rosenblatt DS, Vuchich M-J, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood. 1990;76(1):44\u20139.","journal-title":"Blood"},{"issue":"11","key":"726_CR33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/00498254.2017.1397812","volume":"48","author":"P Shi","year":"2018","unstructured":"Shi P, Liao M, Chuang BC, Griffin R, Shi J, Hyer M, et al. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles. Xenobiotica. 2018;48(11):1173\u201383.","journal-title":"Xenobiotica"},{"issue":"1","key":"726_CR34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejps.2003.07.003","volume":"21","author":"LM Chan","year":"2004","unstructured":"Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci. 2004;21(1):25\u201351.","journal-title":"Eur J Pharm Sci"},{"issue":"10","key":"726_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/FPC.0b013e328343dd93","volume":"21","author":"TS Mikkelsen","year":"2011","unstructured":"Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genom. 2011;21(10):679\u201386.","journal-title":"Pharmacogenet Genom"},{"issue":"19","key":"726_CR36","first-page":"7225","volume":"61","author":"H Zeng","year":"2001","unstructured":"Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001;61(19):7225\u201332.","journal-title":"Cancer Res"},{"issue":"8","key":"726_CR37","first-page":"3458","volume":"61","author":"M Maliepaard","year":"2001","unstructured":"Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458\u201364.","journal-title":"Cancer Res"},{"issue":"2","key":"726_CR38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e32835b8662","volume":"24","author":"K Csordas","year":"2013","unstructured":"Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Anticancer Drugs. 2013;24(2):189\u201397.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"726_CR39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-009-1205-4","volume":"66","author":"T Adam de Beaumais","year":"2010","unstructured":"Adam de Beaumais T, Dervieux T, Fakhoury M, Medard Y, Azougagh S, Zhang D, et al. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2010;66(4):653\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"726_CR40","doi-asserted-by":"publisher","DOI":"10.2298\/VSP190430126R","author":"I Raj\u0161i\u0107","year":"2021","unstructured":"Raj\u0161i\u0107 I, Pavlovi\u0107 N, Milija\u0161evi\u0107 B, Vukmirovi\u0107 S, Spasi\u0107 D, \u017digi\u0107 M, et al. The increasing doses of methotrexate pharmacokinetics after intravenous administration in rats-model selection. Vojnosanit Pregl. 2021. https:\/\/doi.org\/10.2298\/VSP190430126R (OnLine-First Issue).","journal-title":"Vojnosanit Pregl"},{"issue":"12","key":"726_CR41","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0959-8049(96)00230-4","volume":"32A","author":"B Buchholz","year":"1996","unstructured":"Buchholz B, Frei E, Eisenbarth J, Weigand M, Ludwig R. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia. Eur J Cancer. 1996;32A(12):2101\u20137.","journal-title":"Eur J Cancer"},{"issue":"8","key":"726_CR42","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19910415)67:8<2062::AID-CNCR2820670809>3.0.CO;2-U","volume":"67","author":"ED Simmons","year":"1991","unstructured":"Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer. 1991;67(8):2062\u20135.","journal-title":"Cancer"},{"issue":"19","key":"726_CR43","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"726_CR44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0003-9861(82)90235-1","volume":"216","author":"M Balinska","year":"1982","unstructured":"Balinska M, Nimec Z, Galivan J. Characteristics of methotrexate polyglutamate formation in cultured hepatic cells. Arch Biochem Biophys. 1982;216(2):466\u201376.","journal-title":"Arch Biochem Biophys"},{"key":"726_CR45","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"issue":"7","key":"726_CR46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","volume":"29","author":"JM Kremer","year":"1986","unstructured":"Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986;29(7):832\u20135.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"726_CR47","first-page":"121","volume":"16","author":"HM Said","year":"1986","unstructured":"Said HM, Hollander D. Inhibitory effect of bile salts on the enterohepatic circulation of methotrexate in the unanesthetized rat: inhibition of methotrexate intestinal absorption. Cancer Chemother Pharmacol. 1986;16(2):121\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"key":"726_CR48","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104333","volume":"146","author":"S Lazarevic","year":"2019","unstructured":"Lazarevic S, Danic M, Golocorbin-Kon S, Al-Salami H, Mikov M. Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacol Res. 2019;146: 104333.","journal-title":"Pharmacol Res"},{"key":"726_CR49","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fphar.2018.01382","volume":"9","author":"M \u0110anic","year":"2018","unstructured":"\u0110anic M, Stanimirov B, Pavlovic N, Golocorbin-Kon S, Al-Salami H, Stankov K, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol. 2018;9:1382.","journal-title":"Front Pharmacol"},{"issue":"7","key":"726_CR50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1211\/jpp.61.07.0016","volume":"61","author":"G Chen","year":"2009","unstructured":"Chen G, Fawcett JP, Mikov M, Tucker IG. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. J Pharm Pharmacol. 2009;61(7):953\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"726_CR51","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/ijms19041120","volume":"19","author":"MJ Kim","year":"2018","unstructured":"Kim MJ, Kang YJ, Kwon M, Choi YA, Choi MK, Chi HY, et al. Ursodeoxycholate restores biliary excretion of methotrexate in rats with ethinyl estradiol induced-cholestasis by restoring canalicular Mrp2 expression. Int J Mol Sci. 2018;19(4):1120.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"726_CR52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10928-010-9170-4","volume":"37","author":"A Dokoumetzidis","year":"2010","unstructured":"Dokoumetzidis A, Magin R, Macheras P. Fractional kinetics in multi-compartmental systems. J Pharmacokinet Pharmacodyn. 2010;37(5):507\u201324.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-021-00726-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-021-00726-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T21:40:11Z","timestamp":1725918011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-021-00726-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s13318-021-00726-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"27 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by the Horizon 2020 Medlem Project (no. 690876) and project no. 41012 of the Ministry of Education and Science of the Republic of Serbia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The study was approved by the Institute for Child and Youth Health Care of Vojvodina Ethics Committee and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from legal guardians.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Legal guardians of the patients signed an informed consent to the publication of their data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"IR and SV conceived of the presented idea. IR, SL and M\u0110 carried out the experiment and wrote the manuscript. IR, SV and AM contributed to designing the experiments, analyzing and interpreting the data. SG-K and HA-S provided critical revision. MM supervised the study. All authors reviewed and approved the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}